BALL Score for Relapsed/Refractory CLL

ورودی‌های بالینی بیمار

حداقل ۰.۱ — حداکثر ۵۰ • واحد: mg/dL

حداقل ۳ — حداکثر ۲۰ • واحد: g/dL

حداقل ۵۰ — حداکثر ۵۰۰۰ • واحد: U/L

حداقل ۱۰۰ — حداکثر ۵۰۰ • واحد: U/L

حداقل ۰ — حداکثر ۶۰۰ • واحد: months

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
ball score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–1
  • Intermediate Risk2–3
  • High Risk4–4
Direct Clinical Answer

The BALL Score for Relapsed/Refractory CLL calculates assessing prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) on targeted therapies. Key inputs include beta2 microglobulin. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Assesses prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) on targeted therapies. The BALL Score (β2-microglobulin, Anemia, LDH, Last Therapy) helps estimate survival outcomes in patients with R/R-CLL who require further treatment with targeted therapies.

Clinical Indication

The BALL Score for Relapsed/Refractory CLL is indicated for bedside clinical practice to support Assesses prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) on targeted therapies. The BALL Score (β2-microglobulin, Anemia, LDH, Last Therapy) helps estimate survival outcomes in patients with R/R-CLL who require further treatment with targeted therapies.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

BALL Score = β2-microglobulin points + Anemia points + LDH points + Last therapy points

Input Parameters

NameTypeRequiredDescription
beta2_microglobulinfloatYesBeta-2-microglobulin level(mg/dL)
hemoglobinfloatYesHemoglobin level(g/dL)
sexstringYesPatient's biological sex
ldhfloatYesLactate dehydrogenase (LDH) level(U/L)
ldh_upper_limitfloatYesUpper limit of normal for LDH (lab-specific)(U/L)
months_since_last_therapyintegerYesMonths since initiation of last therapy(months)

Score Interpretation & Guidance

RangeStageDescription
0–1Low RiskLow risk group
2–3Intermediate RiskIntermediate risk group
4–4High RiskHigh risk group

Evidence-Based References (EBM)

  • Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, et al. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 Jun;60(6):1438-1446. doi: 10.1080/10428194.2018.1540782.DOI: 10.1080/10428194.2018.1540782
  • Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019 Jul;6(7):e366-e374. doi: 10.1016/S2352-3026(19)30085-7.DOI: 10.1016/S2352-3026(19)30085-7
  • Gentile M, Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, et al. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0816-y.DOI: 10.1038/s41375-020-0816-y

Related calculators